Serina Therapeutics CEO to Present at H.C. Wainwright Conference
Event summary
- Serina Therapeutics CEO Steve Ledger to present at H.C. Wainwright conference on September 14-16, 2026.
- Company will participate in one-on-one investor meetings during the event.
- Presentation available for on-demand viewing starting September 14, 2026, at 7:00 a.m. ET.
- Serina's lead program, SER-252 (POZ-apomorphine), targets advanced Parkinson’s disease.
The big picture
Serina Therapeutics is leveraging the H.C. Wainwright conference to showcase its proprietary POZ Platform and lead program, SER-252, amid a competitive landscape in neurological disease treatments. The event provides a critical platform for investor engagement and strategic positioning as the company advances its clinical-stage pipeline. The broader biotech sector continues to focus on innovative drug optimization technologies, making Serina’s presentation a key watchpoint for industry trends and governance shifts.
What we're watching
- Clinical Progress
- How the presentation will highlight advancements in SER-252 and other pipeline candidates.
- Investor Sentiment
- Whether the conference will boost investor confidence in Serina’s long-term strategy.
- Market Positioning
- The pace at which Serina can differentiate itself in the competitive neurological disease treatment space.
Related topics